A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
Top Cited Papers
Open Access
- 11 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 14 (13) , 1745-1751
- https://doi.org/10.1093/hmg/ddi180
Abstract
Warfarin, a commonly prescribed anticoagulant, exhibited large inter-individual and inter-ethnic differences in the dose required for its anticoagulation effect. Asian populations, including Chinese, require a much lower maintenance dose than Caucasians, for which the mechanisms still remain unknown. We determined DNA sequence variants in CYP2C9 and VKORC1 in 16 Chinese patients having warfarin sensitivity (≤1.5 mg/day, n=11) or resistance (≥6.0 mg/day, n=5), 104 randomly selected Chinese patients receiving warfarin, 95 normal Chinese controls and 92 normal Caucasians. We identified three CYP2C9 variants, CYP2C9*3, T299A and P382L, in four warfarin-sensitive patients. A novel VKORC1 promoter polymorphism (−1639 G>A) presented in the homozygous form (genotype AA) was found in all warfarin-sensitive patients. The resistant patients were either AG or GG. Among the 104 randomly selected Chinese patients receiving warfarin, AA genotype also had lower dose than the AG/GG genotype (PP<0.0001). The promoter polymorphism abolished the E-box consensus sequences and dual luciferase assay revealed that VOKRC1 promoter with the G allele had a 44% increase of activity when compared with the A allele. The differences in allele frequencies of A/G allele and its levels of VKORC1 promoter activity may underscore the inter-individual differences in warfarin dosage as well as inter-ethnic differences between Chinese and Caucasians.Keywords
This publication has 29 references indexed in Scilit:
- Anticoagulant-induced intracerebral bleeding in brain ischemiaActa Neurologica Scandinavica, 2009
- Novel genetic variants in Asian subjects and their influence on maintenance warfarin doseClinical Pharmacology & Therapeutics, 2004
- Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patientsClinical Pharmacology & Therapeutics, 2003
- Interindividual variability in sensitivity to warfarin-Nature or nurture?Clinical Pharmacology & Therapeutics, 2001
- Molecular Basis of Ethnic Differences in Drug Disposition and ResponseAnnual Review of Pharmacology and Toxicology, 2001
- Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic RangeChest, 2001
- Factors determining the maintenance dose of warfarin in Chinese patientsQJM: An International Journal of Medicine, 1996
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart ValvesChest, 1995
- Antithrombotic Therapy in Atrial FibrillationChest, 1995
- Antithrombotic therapy in deep vein thrombosis and pulmonary embolismAmerican Heart Journal, 1992